Spero Therapeutics (SPRO) Given a $30.00 Price Target at Oppenheimer
Spero Therapeutics (NASDAQ:SPRO) received a $30.00 target price from research analysts at Oppenheimer in a research note issued to investors on Thursday. The firm presently has a “buy” rating on the stock. Oppenheimer’s price target would indicate a potential upside of 150.21% from the stock’s current price.
Other analysts have also recently issued research reports about the stock. Bank of America assumed coverage on shares of Spero Therapeutics in a research note on Monday, November 27th. They issued a “neutral” rating on the stock. Stifel Nicolaus assumed coverage on shares of Spero Therapeutics in a research note on Monday, November 27th. They issued a “buy” rating and a $26.00 target price on the stock. Finally, Cowen assumed coverage on shares of Spero Therapeutics in a research note on Monday, November 27th. They issued an “outperform” rating on the stock.
Shares of Spero Therapeutics (NASDAQ:SPRO) opened at $11.99 on Thursday. The firm has a market cap of $172.29 and a PE ratio of -4.21. Spero Therapeutics has a 52 week low of $9.84 and a 52 week high of $15.40.
Spero Therapeutics (NASDAQ:SPRO) last posted its earnings results on Thursday, December 14th. The company reported ($36.02) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($2.43) by ($33.59). The company had revenue of $0.60 million for the quarter, compared to analyst estimates of $0.20 million. equities analysts anticipate that Spero Therapeutics will post -8.52 earnings per share for the current fiscal year.
In other news, major shareholder Plc Glaxosmithkline purchased 428,571 shares of Spero Therapeutics stock in a transaction on Monday, November 6th. The shares were purchased at an average cost of $14.00 per share, for a total transaction of $5,999,994.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Casper Breum purchased 214,285 shares of Spero Therapeutics stock in a transaction on Monday, November 6th. The stock was purchased at an average price of $14.00 per share, for a total transaction of $2,999,990.00. The disclosure for this purchase can be found here. In the last three months, insiders purchased 649,356 shares of company stock worth $9,090,984.
About Spero Therapeutics
SmartPros Ltd. is engaged in provision of learning and educational solutions in content areas that target specific markets, including accounting/finance, legal, engineering, securities and insurance. The Company also provides education in banking, finance, taxation, information technology, health and safety, human resources and compliance for the general corporate market.
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.